Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

PURPOSE: The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seok Jin, Yoon, Dok Hyun, Kim, Jin Seok, Kang, Hye Jin, Lee, Hye Won, Eom, Hyeon-Seok, Hong, Jung Yong, Cho, Junhun, Ko, Young Hyeh, Huh, Jooryung, Yang, Woo-Ick, Park, Weon Seo, Lee, Seung-Sook, Suh, Cheolwon, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176958/
https://www.ncbi.nlm.nih.gov/pubmed/31476851
http://dx.doi.org/10.4143/crt.2019.198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176958/
https://www.ncbi.nlm.nih.gov/pubmed/31476851
http://dx.doi.org/10.4143/crt.2019.198

Ejemplares similares